View Filing Data

Computers and office equipment

Leasehold improvements

Manufacturing Tooling

Demo Equipment

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2018	Mar. 26, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	0001446159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		15,792,586
Entity Public Float			$ 13,584,316
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash & cash equivalents	$ 162,152	$ 766,189
Certificates of deposit		244,971
Accounts Receivable	232,602	137,499
Notes Receivable (inclusive of $452,775 in advances to Helomics)	497,276	667,512
Inventories	241,066	265,045
Prepaid Expense and other assets	318,431	289,966
Total Current Assets	1,451,527	2,371,182
Notes Receivable	1,112,524	1,070,000
Fixed Assets, net	180,453	87,716
Intangibles, net	964,495	95,356
Total Assets	3,708,999	3,624,254
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	445,689	140,462
Notes Payable – Bridge Loan Net of Discount	1,327,942
Notes Payable – Net of Discount	306,972
Accrued Expenses	1,279,114	785,215
Derivative Liability	272,745
Deferred Revenue	23,065	6,663
Total Current Liabilities	3,655,527	932,340
Total Liabilities	3,655,527	932,340
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 14,091,748 and 6,943,283 outstanding	140,917	69,432
Additional paid-in capital	(63,019,708)	(55,636,680)
Accumulated deficit	63,107,945	53,021,469
Total Stockholders' Equity	53,472	2,691,914
Total Liabilities and Stockholders' Equity	3,708,999	3,624,254
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock		$ 6,479

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	14,091,748	6,943,283
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 1,411,655	$ 654,836
Cost of goods sold	415,764	148,045
Gross margin	995,891	506,791
General and administrative expense	4,626,997	4,050,307
Operations expense	1,861,121	1,414,774
Sales and marketing expense	2,369,152	1,095,232
Total operating loss	7,861,379	6,053,523
Other income	510,254	53,734
Other expense	441,772	3,228
Loss on equity method investment	(2,293,580)
Net loss available to common shareholders	$ (10,086,477)	$ (6,003,017)
Loss per common share - basic and diluted (in dollars per share)	$ (0.79)	$ (0.94)
Weighted average shares used in computation - basic and diluted (in shares)	12,816,289	6,362,989

Consolidated Statements of Stockholders' Equity - USD ($)	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member] Retained Earnings [Member]	Over-Allotment Option [Member]	Private Placement [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Common Stock [Member]	Consulting Agreement Two [Member] Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	Consultant Contract One [Member] Common Stock [Member]	Consultant Contract One [Member] Additional Paid-in Capital [Member]	Consultant Contract One [Member]	Consultant Contract Two [Member] Common Stock [Member]	Consultant Contract Two [Member] Additional Paid-in Capital [Member]	Consultant Contract Two [Member]	Contract with TumorGenesis [Member] Common Stock [Member]	Contract with TumorGenesis [Member] Additional Paid-in Capital [Member]	Contract with TumorGenesis [Member]	Helomics Holding Corp. [Member] Common Stock [Member]	Helomics Holding Corp. [Member] Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member]	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Series E Warrants [Member]	Re-priced Warrants [Member] Common Stock [Member]	Re-priced Warrants [Member] Additional Paid-in Capital [Member]	Re-priced Warrants [Member]	Bridge Loan Warrants [Member] Additional Paid-in Capital [Member]	Bridge Loan Warrants [Member]	Note Payable Warrants [Member] Additional Paid-in Capital [Member]	Note Payable Warrants [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2016																																										$ 792	$ 45,644	$ 47,894,196	$ (47,018,451)	$ 1,501	$ 923,682
Balance (in shares) at Dec. 31, 2016																																									79,246		4,564,428
Shares issued pursuant to the public offering	$ 1,750	$ 392,000		$ 393,750		$ 12,138	$ 1,201,681	$ 1,213,819							$ 500	$ 78,500	$ 79,000																										$ 17,500	3,403,688			3,421,188
Shares issued pursuant to the public offering (in shares)	175,000				1,213,819										50,000																												1,750,000
Vesting Expense																																												2,298,680			2,298,680
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																																											$ (4,000)				(4,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																																											(400,000)
Shares issued for services									$ 1,000	$ 219,000	$ 220,000	$ 433	$ 63,699	$ 64,132
Shares issued for services (in shares)									100,000			43,333
Unrealized (loss) from marketable securities																																													(1)	(1,501)	(1,501)
Preferred conversion to common shares pursuant to a private placement agreement																																										(5,659)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																								(566,000)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																											660,522
Preferred conversion to common shares pursuant to a private placement agreement																																											$ 6,604	85,236			86,182
Net loss																																													(6,003,017)		(6,003,017)
Balance at Dec. 31, 2017																																										7,271	$ 69,432	55,636,680	(53,021,469)		2,691,914
Balance (in shares) at Dec. 31, 2017																																								647,819	79,246		6,943,283
Shares issued pursuant to the public offering	$ 2,153	$ 202,268	$ 1	$ 204,422																																							$ 29,000	2,726,087			2,755,087
Shares issued pursuant to the public offering (in shares)	215,247																																										2,900,000
Vesting Expense																																												1,124,928			1,124,928
Shares issued for services																		$ 1,500	$ 175,500	$ 177,000	$ 1,000	$ 117,000	$ 118,000
Shares issued for services (in shares)																		150,000			100,000
Preferred conversion to common shares pursuant to a private placement agreement																																										(6,479)					(6,479)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																								(647,819)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																																											589,747
Preferred conversion to common shares pursuant to a private placement agreement																																											$ 5,897	582
Net loss																																													(10,086,477)		(10,086,477)
Balance at Dec. 31, 2018																																										792	$ 140,917	63,019,708	(63,107,945)		53,472
Balance (in shares) at Dec. 31, 2018																																									79,246		14,091,748
Investment in Subsidiary pursuant to Helomics 20% acquisition																											$ 11,000	$ 1,031,250	$ 1,042,250
Investment in Subsidiary pursuant to Helomics 20% acquisition (in shares)																											1,100,000
Warrant exercises																														$ 1,454	$ 143,942	$ 145,396	$ 5,046	$ 499,619	$ 504,665
Warrant exercises (in shares)																														145,396			504,666
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share																								$ 7,500	$ 870,000	$ 877,500
Shares issued in escrow pursuant to a contract with TumorGenesis @ $1.17 per share (in shares)																								750,000
Debt Discount on Warrants																																				$ 183,187	$ 183,187	$ 68,757	$ 68,757
Shares issued as inducement for Bridge Loan																																											$ 6,500	200,105			206,605
Shares issued as inducement for Bridge Loan (in shares)																																											650,000
Shares issued to employee in lieu of bonus																																											$ 435	$ 39,803			$ 40,238
Shares issued to employee in lieu of bonus (in shares)																																											43,409

Consolidated Statements of Stockholders' Equity (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Investor Relations Consultant [Member]
Price of shares issued (in dollars per share)		$ 1.18
Consultant Contract One [Member] \| Common Stock [Member]
Price of shares issued (in dollars per share)	$ 1.18
Consultant Contract Two [Member] \| Common Stock [Member]
Price of shares issued (in dollars per share)	1.18
Contract with TumorGenesis [Member] \| Common Stock [Member]
Price of shares issued (in dollars per share)	1.17
Series E Warrants [Member] \| Common Stock [Member]
Warrant exercises, exercise price per share (in dollars per share)	1
Common Stock [Member] \| Over-Allotment Option [Member]
Price of shares issued (in dollars per share)	$ 0.9497

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Cash flow from operating activities:
Net loss	$ (10,086,477)	$ (6,003,017)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment	2,293,580
Depreciation and amortization	147,628	71,562
Vesting expense for stock options and warrants	1,124,928	2,298,680
Equity instruments issued for management and consulting	335,238	359,133
Amortization of debt discount	385,111
Gain from sale of marketable securities		(1,837)
Gain on valuation of equity-linked instruments	(372,263)
Changes in assets and liabilities:
Accounts receivable	(95,103)	(98,580)
Inventories	23,979	7,163
Prepaid expense and other assets	139,895	(141,329)
Accounts payable	305,227	(79,650)
Accrued expenses	493,899	(870,540)
Deferred revenue	16,402	(1,335)
Net cash used in operating activities	(5,287,956)	(4,459,750)
Cash flow from investing activities:
Proceeds from sale of marketable securities		284,665
Purchase of certificates of deposit		(3,084,971)
Redemption of certificates of deposit	244,971	2,940,000
Advances on notes receivable	(1,123,619)	(1,737,512)
Purchase of fixed assets	(177,732)	(45,093)
Purchase of intangibles	(54,271)	(10,179)
Net cash used in investing activities	(1,110,651)	(1,653,090)
Cash flow from financing activities:
Proceeds from exercise of warrants into common stock	650,061
Proceeds from debt issuance	2,185,000
Net proceeds from issuance of preferred stock		1,300,001
Proceeds from Issuance of Common Stock	2,959,509	3,814,938
Net cash provided by financing activities	5,794,570	5,114,939
Net decrease in cash	(604,037)	(997,901)
Cash at beginning of period	766,189	1,764,090
Cash at end of period	162,152	766,189
Non-cash transactions in investing and financing activities
Conversion of preferred stock to common stock	6,479
Equity method investment – Helomics	1,542,250
Licensing Fee for Tumorgenesis [Member]
Non-cash transactions in investing and financing activities
Stock issued for fees	$ 877,500

Note 1 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE

— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

The Company was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On

February 1, 2018,

the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Certificate of Incorporation to change the Company’s corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective

February 1, 2018.

Because of this change, the Company’s common stock began trading under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

December 31, 2018,

the registrant had

14,091,748

shares of common stock, par value

$.01

per share, outstanding. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of its proprietary cleaning fluid and filters to users of the STREAMWAY systems. In

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement – see Note

The Company’s precision medicine services – designed to use artificial intelligence and a comprehensive disease database to improve the effectiveness of cancer therapy – were launched with the Company’s investment in Helomics. Helomics’ precision oncology services are based on its D-CHIP™ diagnostic platform, which combines a database of genomic and drug response profiles from over

149,000

tumors with an artificial intelligence based searchable bioinformatics platform. Once a patient’s tumor is excised and analyzed, the D-CHIP platform compares the tumor profile with its database, and using its extensive drug response data, provides a specific therapeutic roadmap. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc. (“TumorGenesis”), to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis, formed during the

first

quarter, is presented as part of the consolidated financial statements (“financial statements”).

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of

$63,107,945.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. In

2018,

the Company incurred negative operating cash flows of approximately

$441,000

per month. Although the Company has attempted to curtail expenses, there is

guarantee that the Company will be able to reduce these expenses significantly, and expenses

may

need to be higher to prepare product lines for broader sales in order to generate sustainable revenues.

The Company had cash and cash equivalents of

$162,152

as of

December 31, 2018

and needs to raise significant additional capital to meet its operating needs, pay debt obligations coming due, and the continued operating needs of Helomics, therefore there is substantial doubt about the Company’s ability to continue as a going concern for

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty. The Company has available financing options including a shelf registration statement on Form S-

with which the Company has raised approximately

$2.1

million in net proceeds in early

2019.

The Company

may

raise up to approximately

$1.7

million in additional gross proceeds in the next calendar year using the shelf registration statement. This amount of available financing will increase to approximately

$6.4

million in additional gross proceeds, once the Helomics acquisition is completed.

Since inception to

December 31, 2018,

the Company raised approximately

$36,490,000

in equity and

$7,870,000

in debt financing. Equity raises include: a

January 2017

public offering of units with gross proceeds to the Company of

$3,937,500;

November 2017

private placement with gross proceeds of

$1,300,000;

and, a

January 2018

public offering with gross proceeds of

$2,755,000.

Included in debt financing were raises in

September 2018

on senior secured promissory notes with net proceeds of

$1,815,000,

and in

November 2018

the Company received a loan from the CEO for

$370,000.

Subsequent to

December 31, 2018,

the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional

$1,300,000.

The Company has

commitments or contingencies.

Recent Accounting Developments

Accounting Policies and Estimates

The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning

January

2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018,

and there was

material impact. See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

). The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do

not

result in consolidation and are

not

accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The Company adopted the standard as of

January 1, 2018.

As of

December 31, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after

December 15, 2018.

Early adoption is permitted. The Company adopted ASU

2016

January 1, 2019,

using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. The adoption resulted in

material impact to the Company’s balance sheet, results of operations, equity or cash flows.

August 2016,

the FASB issued ASU

No.

2016

15,

Statement of Cash Flows (Topic

230

): Classification of Certain Cash Receipts and Cash Payments,

to address diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The amendments are effective for public business entities for fiscal years beginning after

December 15, 2017,

and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method to each period presented. If retrospective application is impractical for some of the issues addressed by the update, the amendments for those issues would be applied prospectively as of the earliest date practicable. Early adoption is permitted, including adoption in an interim period. The Company adopted the standard as of

January 1, 2018.

As of

December 31, 2018,

there is

material impact on the Company’s financial statements and disclosures.

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment in accordance with ASC

360

— Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are definite lived and currently solely the costs of obtaining licensing fees, trademarks, and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

Advertising

Advertising costs are expensed as incurred. Advertising expenses were

$43,548

2018

and

$37,060

2017.

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were approximately

$526,000

and

$289,000

for

2018

and

2017,

respectively.

Revenue Recognition

The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases.

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses.

Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company

may,

at its discretion, negotiate different shipping terms with customers which

may

affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally

days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company.

Customers

may

also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of

one

year subsequent to the

one

-year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the

one

-year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers.

All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold.

Variable Consideration

The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do

not

contain any features that create variability in the amount or timing of revenue to be earned.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s

Accounting Standards Certification

(ASC)

820,

fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities, which in

2018

are cash equivalents only, were determined based on Level

inputs.

Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts. Changes to the valuation allowance have

not

been material to the financial statements.

Inventories

Inventories are stated at the net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	December 31, 2018		December 31, 2017

Finished goods	$	58,701	$	62,932
Raw materials		127,003		141,028
Work-In-Process		55,362		61,085
Total	$	241,066	$	265,045

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Depreciation is shown in the financial statements under fixed assets, net on the balance sheet, and amortization is shown under intangibles, net on the balance sheet. Estimated useful asset life by classification is as follows:

The Company’s investment in fixed assets consists of the following:

	December 31, 2018		December 31, 2017
Computers and office equipment	$	204,903	$	183,528
Leasehold Improvements		140,114		25,635
Manufacturing Tooling		108,955		108,955
Demo Equipment		85,246		43,368
Total		539,218		361,486
Less: Accumulated Depreciation		358,765		273,770
Total Fixed Assets, Net	$	180,453	$	87,716

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Depreciation expense was

$84,995

2018

and

$58,872

2017.

Intangible Assets

The components of intangible assets all of which are finite-lived were as follows:

	12/31/2018							12/31/2017
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	318,304	$	(182,559	)	$	135,745	$	264,032	$	(168,676	)	$	95,356
Licensing Fees		877,500		(48,750	)		828,750		-		-			-
Total	$	1,195,804	$	(231,309	)	$	964,495	$	264,032	$	(168,676	)	$	95,356

The following table outlines the estimated future amortization expense related to intangible assets held as of

December 31, 2018

Year ending	Expense
2019		72,383
2020		72,383
2021		72,383
2022		72,383
2023		72,383
Thereafter		602,580
Total		964,495

Intangible assets consist of trademarks, patent costs and licensing fees. Amortization expense was

$62,633

2018

and

$12,689

2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Taxes

December 22, 2017,

the Tax Cuts and Jobs Act of

2017

(Tax Reform Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry-forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced the U.S. corporate income tax rates from

34%

21%.

As a result of the enacted law, the Company was required to value its deferred tax assets and liabilities at the new enacted rate. There was

income tax impact from the re-measurement due to the

100%

valuation allowance on the Company’s deferred tax assets.

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Offering Costs

Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any

one

financial institution. The Company has

credit risk concentration because there are

funds in excess of insurance limits in a single bank.

Product Warranty Costs

2018

and in

2017,

the Company incurred approximately

$10,682

and

$6,209,

respectively in warranty costs.

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. These segments are its domestic operations and international operations. Substantially all the Company’s assets, revenues, and expenses for the years ended

December 31, 2018

and

2017

were located at or derived from operations in the United States. In

2018

and

2017,

business activity within the Company’s international segment was immaterial.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 2 - Equity Method Investment

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE

– EQUITY METHOD INVESTMENT

The Company has an equity method investment in Helomics. Summarized financial information for Helomics is presented below:

Helomics Holdings Corporation

	December 31, 2018

Current assets	$	419,266

Non-current assets	$	2,046,347

Total assets	$	2,465,613

Current liabilities	$	12,247,174

Total liabilities	$	12,247,174

	For the Year-ended Ended
	December 31, 2018
Revenue	$	523,546

Gross margin	$	214,426

Net loss on operations	$	(5,056,725	)

Net loss	$	(9,452,835	)

Net Loss to investee	$	(7,159,255	) 1

The loss to investee was calculated at

80%

for the initial period of ownership,

January 11, 2018 –

February 27, 2018,

and then at

75%

for the remainder of the

twelve

-month period at the current equity investment percentage owned by the Company.

Helomics’

first

year predominantly included diagnostic revenue only. The contract research organization and D-CHIP Artificial Intelligence products are in the process of launching and have generated approximately

$31,000

of revenue in the year-to-date.

The Helomics loss reduces the equity method investment asset on the balance sheet. The recorded investor losses have exceeded the equity method investment originally recorded total. As such, the equity method investment recorded to the balance sheet has been reduced to

zero

, and all subsequent losses reduced the note receivable due from Helomics. The note receivable on the balance sheet includes

$413,683,

not

including interest, for Helomics. The actual note due to the Company as of

December 31, 2018

$1,165,013.

The amount exceeding the original equity method investment and thus reducing the note receivable balance is

$751,330.

Note 3 - Revenue Recognition	12 Months Ended
Note 3 - Revenue Recognition	Dec. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 – REVENUE RECOGNITION Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company. Customers may also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one -year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one -year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers. All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned. Warranty The Company generally provides one -year warranties against defects in materials and workmanship and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect. Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2018, and December 31, 2017, accounts receivable totaled $232,602 and $137,499, respectively. The Company deferred revenues related primarily to maintenance plans of $23,065 and $6,663 as of December 31, 2018 and December 31, 2017, respectively. Practical Expedients The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components.

Note 4 - Stockholders’ Equity (Deficit), Stock Options and Warrants

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

– STOCKHOLDERS’ EQUITY (DEFICIT), STOCK OPTIONS AND WARRANTS

2017

Firm Commitment Public Offering

January 19, 2017,

the Company closed a firm commitment public offering for

1,750,000

Units at

$2.25

per Unit. The Units comprised

one

share of common stock and

0.2

Series D Warrants with each whole Series D Warrant purchasing

one

share of the Company’s common stock at an exercise price of

$2.25

per share. The Company received gross proceeds of

$3,937,500.

Subsequently the underwriter exercised over-allotment for

175,000

shares of common stock and for Series D warrants to purchase

35,000

shares of common stock at

$0.01

per warrant. The Company received net proceeds from the over-allotment of

$358,312.

2017

Private Placement

November 30, 2017,

the Company closed a private placement of a newly created series of preferred stock designated as “Series C Convertible Preferred Stock” with a New York based Family Office. Pursuant to the Securities Purchase Agreement, the investor purchased

1,213,819

shares of Series C stock at a purchase price of

$1.071

per Series C Share, together with a warrant to purchase up to

606,910

shares of common stock. The warrant has an exercise price of

$1.26

per share, subject to adjustment, has a

five

- and

one

-half-year term and is exercisable commencing

six

months following the date of issuance. Total gross proceeds to the Company were

$1,300,000

before deducting expenses and will be used for general working capital. In connection with the offering and pursuant to a registration rights agreement, the Company has agreed to file a “resale” registration statement covering all of the shares of common stock issuable upon conversion of the warrant. Pursuant to the Securities Purchase agreement, and as of this filing date, all the Preferred Series C shares were converted at a conversion rate of

1.167

to a maximum of

1,250,269

shares of common stock. The remaining

142,466

shares of Preferred Series C stock were cancelled with a redemption payment to the holder for

$189,285.

2018

Firm Commitment Public Offering

January 2018,

the Company completed a firm commitment underwritten public offering of

2,900,000

Units at an offering price of

$0.95

per Unit, with each Unit consisting of

one

share of the Company’s common stock and

0.3

of a Series E Warrant, with each whole Series E Warrant purchasing

one

share of common stock at an exercise price of

$1.00

per whole share. The shares of common stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately

$2,755,000,

before deducting expenses. The Company granted the underwriter a

-day option to purchase an additional (i) up to

290,000

additional shares of common stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to

87,000

additional shares of common stock at a purchase price of

$0.001

per Series E Warrant to cover over-allotments, if any. On

February 21, 2018,

the underwriter exercised on

215,247

shares of common stock, par value

$0.01,

$0.9497

per share as described in the Underwriting Agreement. The Company received net proceeds of

$188,066

after deductions of

$16,354

representing the underwriter’s discount of

of the purchase price of the shares.

Share Exchange Agreement with Helomics

January 11, 2018,

the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement, Helomics issued

2,500,000

shares of its Series A Preferred Stock in exchange for

1,100,000

shares of common stock. Under the share exchange agreement, in

March 2018

the Company converted

$500,000

in secured notes into another

of Helomics’ outstanding shares, which resulted in the Company owning

25%

of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of

$500,000

to Helomics. The

1,100,000

shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Company’s shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Company shares will be released to Helomics following a determination that Helomics’ revenues in any

-month period have been equal or greater than

$8,000,000.

The Helomics Preferred Stock issued to the Company is convertible into an aggregate of

20%

of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics

may

take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends.

Merger Agreement with Helomics

June 28, 2018,

the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Helomics and certain other entities. On

October 26, 2018,

the Merger Agreement was amended and restated. The Merger Agreement contemplated a reverse triangular merger with Helomics surviving the merger and becoming a wholly-owned operating subsidiary of the Company (the “Merger”). At the time of the Merger, all outstanding shares of Helomics stock

not

already held by the Company were to be converted into the right to receive a proportionate share of

7.5

million shares of newly issued common stock in the Company (“Merger Shares”), in addition to the

1.1

million shares of the Company’s common stock already issued to Helomics for the Company’s initial

20%

ownership in Helomics. Additionally,

860,000

shares of the merger consideration were to be held in escrow for

months to satisfy indemnification claims. Helomics currently has outstanding

$7.6

million in promissory notes and warrants to purchase

18.7

million shares at an exercise price of

$1.00

per share of Helomics common stock held by the investors in the promissory notes. As a result of the Merger, the holders of said promissory notes and warrants would be entitled to additional warrants to purchase up to

5.0

million additional shares of Helomics common stock at an exercise price of

$1.00

per share. Helomics agreed to use commercially reasonable efforts to cause the holder of each such promissory note to enter into an agreement whereby such holder agrees that, effective upon the closing of the Merger, (a) all or a certain portion of the indebtedness evidenced by such promissory note shall be converted into common stock in the Company, (b) all of such holder’s Helomics’ warrants shall be converted into warrants of the Company, and (c) the unconverted portion of said indebtedness shall be converted into a promissory note issued by the Company dated as of the closing of the Merger. The Merger is expressly conditioned on the holders of at least

75%

of the

$7.6

million in outstanding Helomics promissory notes agreeing to such an exchange (and the parties contemplate that each Helomics warrant will be exchanged for a Company warrant at a ratio of

0.6

Precision warrants for each Helomics warrant, with an exercise price of

$1.00

per share. If all holders of such notes agreed to the exchange with respect to the full balance of the notes, such holders would receive an aggregate estimated

23.7

million shares of the Company’s common stock and warrants to purchase an additional

14.2

million shares of the Company’s common stock at

$1.00

per share. In addition, Helomics currently has

995,000

warrants held by other parties at an exercise price of

$0.01

per share of Helomics common stock. It is contemplated that these warrants will be exchanged at the time of the closing of the Merger for warrants to purchase

597,000

shares of Precision common stock at

$0.01

per share.

Under the Merger Agreement, completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics.

At a special meeting of stockholders on

March 22, 2019,

the Company’s stockholders approved the Merger Agreement.

July 10

and

11,

2018,

the Company issued

250,000

shares of common stock, par value

$0.01,

$1.18

per share for consulting fees pursuant to the TumorGenesis license fees contract, and

750,000

shares of common stock, par value

$0.01,

$1.17

per share, in escrow, for TumorGenesis license fees pursuant to the TumorGenesis license fees contract.

Increases in Authorized Shares

At a special meeting of the stockholders on

January 29, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

8,000,000

shares to

24,000,000

shares of common stock under the Company’s certificate of incorporation.

At the annual meeting on

December 28, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. The amendment to the certificate of incorporation to affect this increase was filed on

January 2, 2018.

At the special meeting of stockholders on

March 22, 2019,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

50,000,000

100,000,000

shares of common stock,

$0.01

par value. The amendment to the certificate of incorporation to affect this increase was filed on

March 22, 2019.

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to

three

years. Options under this plan have terms ranging from

three

ten

years.

Accounting for share-based payment

ASC

718

–

Compensation – Stock Compensation, (“ASC

718”

)

requires that a company that issues equity as compensation needs to record compensation expense on its statements of comprehensive loss that corresponds to the estimated cost of those equity grants. ASC

718

requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.

Since the Company's common stock has

significant public trading history, and the Company has experienced

significant option exercises in its history, the Company policy is to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company has been on the NASDAQ Capital Market since

2015

and has had a volatile stock including reverse stock splits. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.

April 19, 2017,

the Company terminated the Company’s Partnership and Exclusive Reseller Agreement with GLG Pharma, LLC and thereby received

400,000

shares of common stock, par value

$0.01,

from escrow.

For grants of stock options and warrants in

2017

the Company used a

1.92%

2.40%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.6541

$1.5489

per share.

January 15, 2018,

the Company issued inducement stock options in accordance with NASDAQ listing rule for

50,000

shares of common stock, par value

$0.01

$0.97

per share to the Company’s newly hired International Vice President of Sales. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

March 12, 2018,

the Company issued inducement stock options in accordance with NASDAQ rule for

111,112

shares of common stock, par value

$0.01

$1.35

per share to the Company’s newly hired Vice President of Sales and Marketing. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

For grants of stock option and warrants in

2018

the Company used

2.33%

3.07%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.3816

$1.0044

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		1,098,858			1.01		2,336,154			1.07
Expired		(194,564	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at December 31, 2018		3,669,277		$	1.70		3,626,643		$	4.17

December 31, 2018,

2,946,488

stock options are fully vested and currently exercisable with a weighted average exercise price of

$1.79

and a weighted average remaining term of

8.86

years. There are

2,247,489

warrants that are fully vested and exercisable. Stock-based compensation recognized in

2018

and

2017

was

$1,124,928

and

$2,298,680,

respectively. The Company has

$741,922

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

The following summarizes the status of options and warrants outstanding at

December 31, 2018:

Range of Exercise Prices	Shares		Weighted Average Remaining Life
Options:
$0.619		201,908		10.00
$0.82		60,000		9.91
$0.91		10,000		9.30
$0.965		3,000		9.38
$0.97		191,753		9.02
$1.01		149,110		9.12
$1.06		23,585		9.76
$1.10		86,958		9.46
$1.13		195,931		9.55
$1.15		21,740		9.59
$1.16		66,451		9.59
$1.18		30,000		9.61
$1.20		41,668		9.59
$1.21		30,000		9.61
$1.35		111,112		9.20
$1.454		17,200		8.75
$1.47		2,305,790		8.48
$2.10		14,286		8.25
$2.25		293		7.65
$2.42		20,640		7.64
$2.80		57,145		8.01
$3.75		4,000		7.50
$4.125		3,636		7.75
$4.1975		7,147		7.72
$4.25		3,529		7.25
$5.125		3,902		7.69
$65.75		190		6.81
$73.50		1,157		7.01
$77.50		2,323		6.50
$80.25		187		6.75
$86.25		232		6.25
$131.25		81		3.69
$148.125		928		4.21
$150.00		1,760		3.63
$162.50		123		6.01
$206.25		121		5.75
$248.4375		121		4.54
$262.50		130		4.54
$281.25		529		4.04
$318.75		3		4.35
$346.875		72		5.25
$431.25		306		5.19
$506.25		188		5.00
$596.25		42		4.75
Total		3,669,277

Warrants:
$0.836		221,292		4.92
$1.00		1,063,935		3.76
$1.07		697,946		3.85
$1.155		1,071,776		4.75
$1.3125		86,086		4.75
$2.25		385,000		3.06
$123.75		94,084		1.67
$243.75		2,529		0.59
$309.375		2,850		0.61
$309.50		222		0.85
$506.25		59		0.12
$609.375		862		0.09
Total		3,626,643

Stock options and warrants expire on various dates from

January 2019

December 2028.

The Company’s board of directors had determined that the Company would require additional authorized shares for anticipated equity financings, future equity offerings, strategic acquisition opportunities, and the continued issuance of equity awards under our stock incentive plan to recruit and retain key employees, and for other proper corporate purposes. As a result, the board of directors called a special meeting of the stockholders that took place on

January 29, 2017.

The vote, a proposal to increase the number of authorized shares of common stock from

8,000,000

shares to

24,000,000

shares of common stock under the Company’s certificate of incorporation passed. On

December 28, 2017,

the Company held its annual meeting. Pursuant to the meeting on

January 2, 2018,

the Certificate of Incorporation of the Company was amended to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. Additionally, the stockholders approved an amendment to the Company’s

2012

Plan to (i) increase the reserve of shares of common stock authorized for issuance thereunder to

5,000,000,

(ii) to increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. Pursuant to the annual meeting and the aforementioned approvals, and as explained in the Company’s definitive proxy statement filed with the SEC on

December 4, 2017,

amendments to the

2012

Plan were considered at the

2016

annual meeting but were

not

approved by the required vote. For options to purchase approximately

2.5

million shares granted after the

2016

annual meeting, the grantees agreed

not

to exercise the options prior to further stockholder approval of an increase in the reserve under the

2012

Plan. As a result of the stockholder approval of the amendments at the

2017

annual meeting, these restrictions on exercise were removed on

December 28, 2017.

Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately

$1.9

million in the

fourth

quarter of

2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of outstanding stock options and warrants as of

December 31, 2018

by year of grant:

Stock Options:

Year	Shares		Price
2011		173			281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		836		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		100,294		2.25	–	5.13
2017		2,461,634		1.01	–	2.10
2018		1,098,858		0.62	–	1.35
Total		3,669,277		$0.62	–	596.25

Warrants:

Year	Shares		Price
2014		6,455		243.75	–	609.38
2015		94,151		0.00	–	243.75
2016		252,333			1.00
2017		1,082,946		1.07	–	2.25
2018		2,190,758		0.84	–	1.3125
Total		3,626,643		$0.00	–	609.38

Note 5 - Notes Receivable	12 Months Ended
Note 5 - Notes Receivable	Dec. 31, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5– NOTES RECEIVABLE In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and were due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of ( 8% ) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. CytoBioscience was current in its payments to the Company through and including July 2018. The Company had not received the scheduled interest payments from CytoBioscience for August through yearend. On September 27 and 28, 2018 CytoBioscience, through its parent company (WestMountain; now named InventaBioTech, OTC symbol INVB), made public filings indicating that their notes payable was in default. In October 2018, CytoBioscience communicated to the Company that CytoBioscience is raising capital that it believes will allow it to resume debt service payments, and that CytoBioscience wishes to negotiate an extension to the note. The Company has reached agreement with CytoBioscience on repayment and in February and March 2019 received payments towards the interest due and a portion of the principal. As of December 31, 2018, the Company does not believe a reserve is needed. In October 2017, the Company advanced $600,000 for working capital for Helomics’ business. Additionally, in December 2017, the Company advanced $67,512 to De Lage Landen, a vendor of Helomics, as a fifty percent ( 50% ) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics. The Company now has an equity stake in Helomics totaling 25%. In September 2018, the Company advanced an additional $60,000 for working capital for Helomics’ business. The balance due to the Company is $163,468, plus interest as of September 30, 2018. Subsequently in October 2018, the Company advanced $907,500 for working capital for Helomics’ business. In December 2018, the Company advanced $30,000 to Helomics under the same note. The balance due to the Company at December 31, 2018, is $1,165,013 in principal, plus interest of $29,215. On the balance sheet there is a reduction to the loan of $751,330 due to the equity method accounting losses incurred from Helomics ownership; see Note 2. In January and February 2019, the Company also advanced Helomics $305,000. In March 2019, the Company advanced an additional $420,000 to Helomics from the Form S- 3 public offering that netted the Company approximately $1.1M. The balance to date owed by Helomics is $1,890,013 plus interest. The Company expects that additional advances will be required before the merger is complete. All additional advances are covered by the security interest in certain equipment of Helomics. In addition, Helomics pledged all of its assets as security for the Company’s convertible secured note financing. Upon completion of the merger with Helomics all intercompany notes would be eliminated in their entirety.

Note 6 - Convertible Debt and Derivative Liability	12 Months Ended
Note 6 - Convertible Debt and Derivative Liability	Dec. 31, 2018
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 6 – CONVERTIBLE DEBT AND DERIVATIVE LIABILITY Effective September 28, 2018 ( the “Effective Date”), the Company issued convertible secured promissory notes to two private investors in the original principal amount of an aggregate $2,297,727 (the “bridge loan”). The Company and Helomics have granted to each of the investors a security interest in their assets to secure repayment of the notes. The securities purchase agreements with the investors also provide for a second investment of an aggregate of $500,000 by the investors at the consummation of the Merger transaction with Helomics, at which point the aggregate principal amounts of the notes will become $2,865,909. As additional consideration for the investment, the Company issued an aggregate 650,000 shares of its common stock (the “Inducement Shares”) to the investors or their affiliates plus warrants to acquire up to an aggregate 1,071,776 shares of the Company’s common stock at an exercise price of $1.155 per share. Upon the closing of the second tranche investment, the warrants would be increased to cover an aggregate total of 1,336,805 shares. Each warrant is exercisable by the investor beginning on the sixth month anniversary of the effective date through the fifth -year anniversary thereof. The notes accrue interest at a rate of 8% per annum (with twelve months of interest guaranteed). The maturity date of the notes is twelve months from the Effective Date. Upon the earlier to occur of an event of default (as defined in the notes) or the filing of certain registration statements, each investor will have the right at any time thereafter to convert all or any part of its Note into shares of the Company’s common stock at a conversion price which is equal to the lesser of: (i) $1.00 and (ii) 70% of the lowest volume-weighted average price (the “VWAP”) of the Company’s common stock during the 20 -trading day period ending on either the last complete trading day prior to the conversion date, or the conversion date (“Conversion Shares”). The number of Conversion Shares that may be issued is subject to an exchange cap such that the sum of (a) the total number of Conversion Shares plus (b) the number of Inducement Shares is limited to an aggregate 2,678,328 shares. Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using 70% of the VWAP for the 20 trading days preceding the balance sheet date, and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required. The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of 2.94% over five years with a 59% volatility rate pursuant to the Company’s established warrant volatility and a calculated value per warrant of .5361 resulting in a fair value of $574,631. Management concluded that the warrants and Inducement Shares qualify for equity classification. The proceeds from the bridge loan were allocated between the convertible note, warrants, and inducement shares based on the relative fair value of the individual elements. In December 2018, the derivative liability was adjusted for the change in the 70% of the VWAP for the 20 days preceding the balance sheet date and assuming conversion on that date as management believed it is probable that the notes will be convertible based on management’s expectation that additional financing will be required. The derivative liability recorded in September 2018 was $645,008. The fair value of the derivative liability as of December 31, 2018 is $272,745. An unrealized gain for the corresponding change in fair value was recorded to other income in 2018. The value of the embedded derivative was based upon level 3 inputs – see the Fair Value Caption in Note 1.

Note 7 - Loss Per Share

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

- LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Year Ended December 31,
	2018			2017
Numerator:
Net loss available in basic and diluted	$	(10,086,477	)	$	(6,003,017	)

Denominator:
Weighted average common shares outstanding-basic		12,816,289			6,362,989

Effect of dilutive stock options warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-diluted		12,816,289			6,362,989

Loss per common share-basic and diluted	$	(0.79	)	$	(0.94	)

(

) The number of shares underlying options and warrants outstanding as of

December 31, 2018

and

December 31, 2017

are

7,295,921

and

4,716,240,

respectively. The number of shares underlying the preferred stock as of

December 31, 2018

79,246

for Series B Convertible. The number of shares underlying the convertible debt is

3,294,087.

The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Income Taxes

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE

8–

INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Tax Reform Act was enacted

December 22, 2017.

Effective

January 1, 2018

the Tax Reform Act reduced corporate income tax rates from

34%

21%.

Other changes effect operating loss carry-forwards and carrybacks, as well as a repeal of the corporate alternative minimum tax. As a result of the Tax Reform Act, deferred tax assets and liabilities were re-measured to account for the lower tax rates. There was

income tax impact from the re-measurement due to the

100%

valuation allowance on the Company’s deferred tax assets.

There is

federal or state income tax provision in the accompanying statements of comprehensive loss due to the cumulative operating losses incurred and

100%

valuation allowance for the deferred tax assets.

Actual income tax benefit (expense) differs from statutory federal income tax benefit (expense) as follows for the years ended

December 31:

	2018			2017
Statutory federal income tax benefit	$	2,118,160		$	2,633,841
State tax benefit, net of federal taxes		66,117			76,922
Foreign tax benefit		132,931			-
Foreign operations tax rate differential		(94,373	)		-
State rate adjustment		15,355			(77,556	)
R&D tax credit		22,532			-
Nondeductible/nontaxable items		(118,905	)		(757,149	)
State NOL adjustment		746,479			-
OID and derivatives		(159,037	)		-
NQSO adjustment		-			537,884
New federal rate adjustment		-			(4,974,121	)
Other		47,868			(8,336	)
Valuation allowance decrease (increase)		(2,777,127	)		2,568,515
Total income tax benefit (expense)	$	-		$	-

Deferred taxes consist of the following as of

December 31:

	2018			2017
Deferred tax assets:
Noncurrent:
Depreciation	$	4,488		$	3,251
Inventory		6,991			6,950
Compensation accruals		60,905			50,436
Accruals and reserves		77,777			64,732
Charitable contribution carryover		3,972			4,068
Derivatives		57,276			-
Related party investments		481,652			-
Intangibles		2,020			-
NQSO compensation		1,019,139			766,648
NOL and credits		9,655,388			7,479,505
Total deferred tax assets		11,369,608			8,375,590

Deferred tax liabilities:
Noncurrent:
Original issue discount		(216,891	)		-
Total deferred tax liabilities		(216,891	)		-

Net deferred tax assets		11,152,717			8,375,590
Less: valuation allowance		(11,152,717	)		(8,375,590	)
Total	$	-		$	-

The Company has determined, based upon its history, that it is probable that future taxable income

may

be insufficient to fully realize the benefits of the net operating loss carryforwards and other deferred tax assets. As such, the Company has determined that a full valuation allowance is warranted. Future events and changes in circumstances could cause this valuation allowance to change.

During

December 2013,

the Company experienced an "ownership change" as defined in Section

382

of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The Company

may

have experienced additional “ownership change(s)” since

December 2013,

but a formal study has

not

yet been performed. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

December 31, 2017,

the Company had approximately

$34,529,255

of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in

2018,

subject to the Section

382

limitation described above. The federal NOLs will expire beginning in

2022

if unused. The Company also had approximately

$12,261,799

of gross NOLs to reduce future state taxable income at

December 31, 2017.

The state NOL’s will expire beginning in

2022

if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At

December 31, 2017,

the federal and state valuation allowances were

$8,129,778

and

$245,812,

respectively.

December 31, 2018,

the Company had approximately

$40,094,472

of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in

2019,

subject to the Section

382

limitation described above. The federal NOLs will expire beginning in

2022

if unused. The Company also had approximately

$12,940,458

of gross NOLs to reduce future state taxable income at

December 31, 2018.

The state NOL’s will expire beginning in

2022

if unused. The Company also had approximately

$421,782

in gross foreign NOLs to reduce future Belgian taxable income at

December 31, 2018.

The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At

December 31, 2018,

the federal, state and foreign valuation allowances were

$9,603,237,

$1,416,758

and

$132,722,

respectively.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities. The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. At

December 31, 2018

and

2017,

the Company recorded

accrued interest or penalties related to uncertain tax positions.

Note 9 - Rent Obligation

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Leases of Lessee Disclosure [Text Block]

NOTE

9–

RENT OBLIGATION

Precision’s corporate offices are located at

2915

Commers Drive, Suite

900,

Eagan, Minnesota

55121.

November 22, 2017,

the Company signed a

second

amendment to its lease last amended on

January 28, 2013.

The lease as amended has a

three

-year term effective

February 1, 2018

ending

January 31, 2021.

The Company leases

5,773

square feet at this location, of which

2,945

square feet is used for office space and

2,828

is used for manufacturing. The Company expects that this space will be adequate for our current office and manufacturing needs.

Skyline Medical Europe’s offices are located at

Chemin de la Fraite –

1380

Ohain, Belgium. The lease agreement was signed

April 24, 2018

and started on

June 15, 2018.

The Company leases around

2,000

square feet at this location,

300

of which is used for storage and

1,250

for office space. The lease is effective through

June 14, 2027.

We expect that this space will be adequate for our current office and storage needs. Rent expense is

3,000

Euros Per month.

Rent expense was

$69,013

and

$66,122

for

2018

and

2017,

respectively.

The Company’s rent obligation for the next

five

years are as follows:

2019	$	80,320
2020		82,320
2021		43,320
2022		40,320
2023		40,320
Thereafter		161,280

Note 10 - Related Party Transactions	12 Months Ended
Note 10 - Related Party Transactions	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 10 - RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no revenue or expenses generated by this partnership to date. Richard L. Gabriel is also contracted as the Chief Operating Officer for TumorGenesis the 100% wholly-owned subsidiary of the Company. Mr. Gabriel receives $12,000 per month pursuant to a renewable six -month contract. The contract extends to March 31, 2019. On November 30, 2018, our CEO, Carl Schwartz, made an investment of $370,000 in the Company and received a note and a common stock purchase warrant for 221,292 warrant shares at $0.836 per share. Effective as of January 8, 2019, Dr. Schwartz made an additional investment of $950,000 and received an amended and restated note in the original principal amount of $1,320,000 and an amended and restated warrant, which added a second tranche of 742,188 warrant shares at an exercise price of $0.704. Each tranche is exercisable beginning on the sixth month anniversary of the date of the related investment through the fifth -year anniversary of the date of the related investment. On January 8, 2019, Dr. Schwartz also purchased 78,125 shares of the Company’s common stock in a private investment for $50,000, representing a price of $0.64 per share, pursuant to a subscription agreement. On February 6, 2019, Dr. Schwartz made an additional investment of $300,000 in the Company and received an amended and restated note in the original principal amount of $1,620,000 and an amended and restated warrant, which added a third tranche of 138,889 warrant shares at an exercise price of $1.188 per share. On February 1, 2019 and the first day of each calendar month thereafter while the note and the warrant remain outstanding, a number of additional shares will be added to the second tranche and the third tranche equal to ( 1 ) one -half percent ( 1/2% ) of the outstanding principal balance of the Note on such date, divided by ( 2 ) the closing price of the Company’s common stock on that date. The number of warrant shares will be subject to a share limit such that the total of (a) the 78,128 shares of common stock purchased by Dr. Schwartz on January 8, 2019, and (b) the total number of warrant shares ( 1,108,596 warrant shares as of February 6, 2019) may not exceed 2,818,350 shares (equal to 19.9% of the outstanding shares of common stock on January 8, 2019). If the second tranche and/or third tranche cannot be increased as required herein due to the share limit, then in lieu of any such increase, the Company shall pay to Dr. Schwartz a cash amount equal to one -half percent ( 1/2% ) of the principal balance of the Schwartz note in lieu of such increase.

Note 11 - Retirement Savings Plans	12 Months Ended
Note 11 - Retirement Savings Plans	Dec. 31, 2018
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 11 – RETIREMENT SAVINGS PLANS The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 (k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2017, and again in 2018, the Company matched 100 %, of the employee’s contribution up to 4.0 % of their earnings. The employer contribution was $51,647 and $29,952 in 2018 and 2017, respectively. There were no discretionary contributions to the plan in 2018 and 2017.

Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounting Changes and Error Corrections [Text Block]	NOTE 12 – CORRECTION OF IMMATERIAL MISSTATEMENT TO PRIOR PERIOD FINANCIAL STATEMENTS During fiscal 2018, the Company identified certain warrants issued in 2016 and 2017, which were incorrectly recognized as expense in 2017 when the warrants vested. As a result, investors stock compensation expense and additional paid-in capital were overstated by $2,150,097 for the year ended December 31, 2017. Also during fiscal 2018, the Company identified that employee stock compensation expense was incorrectly recognized in 2017. As a result, employee stock compensation expenses and additional paid-in capital were understated by $406,522 for the year ended December 31, 2017. Lastly during fiscal 2018, the Company identified that certain nonqualified stock options were excluded from the Company’s tax provision calculation in 2017. As a result, deferred tax assets and the valuation allowance on these assets were understated by $767,000 as of December 31, 2017. Based on an analysis of Accounting Standards Codification (“ASC”) 250 – “Accounting Changes and Error Corrections” (ASC 250” ), Staff Accounting Bulletin 99 – “Materiality” (“SAB 99” ) and Staff Accounting Bulletin 108 – Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements (“SAB 108” ), the Company determined that these costs were immaterial to the previously-issued financial statements. The Company analyzed and considered all relevant quantitative and qualitative factors and determined that the prior fiscal year financial statements should be corrected, even though such revision previously was and continues to be immaterial to the prior year financial statements. Management also determined that such correction to prior fiscal year financial statement for immaterial misstatements would not require previously filed reports to be amended and that such corrections may be made the next time the Company files the prior year financial statements. Accordingly, the Company restated its presentation of general and administrative, sales and marketing, and operating expenses as well as retained earnings and additional paid-in capital in the consolidated financial statements for the year ended December 31, 2018 to reflect such corrections as if they had been recorded in the appropriate fiscal period as of December 31, 2017. Specifically, the adjustments were reflected and corrected in the last quarter of 2017 for the period ended December 31, 2017, by reducing investors stock compensation expense under general and administrative expenses and reducing additional paid-in capital by $ 2,150,097 ; and, by increasing employee stock compensation expenses under general and administrative, selling and operating expense and increasing additional paid-in capital by a total of $ 406,522 on the comparative balance sheet for the period ended December 31, 2017. In addition, the Company restated Note 4 – Stockholders’ Equity (Deficit), Stock Options and Warrants, and Note 8 – Income Taxes, to reflect the impact of these restatements on the footnote disclosures as of and for the year ended December 31, 2017.

Note 13 - Subsequent Events	12 Months Ended
Note 13 - Subsequent Events	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 13 – SUBSEQUENT EVENTS Registered Offering of Common Stock and Warrants On February 27, 2019, Precision Therapeutics Inc., entered into a Placement Agency Agreement (the “Placement Agency Agreement”) pursuant to which Dawson James Securities, Inc. served as placement agent on a “best efforts” basis (the “Placement Agent”) for a registered direct offering in which the Company sold 1,385,000 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 692,500 shares of Common Stock (the “Warrants”) (the “Offering”). The Common Stock and warrants were sold in units (the “Units”), with each Unit consisting of one share of Common Stock and a warrant to purchase 0.5 of a share of the Company’s Common Stock at an exercise price of $1.00 per whole share. The warrants are exercisable at any time on or after the date of issuance and expire on the fifth anniversary of issuance. The Units were sold at a price of $0.90 per Unit, resulting in gross proceeds to the Company of approximately $1.25 million, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agent’s fees and other estimated offering expenses payable by the Company, are expected to be approximately $1.08 million. The closing of the Offering occurred on March 1, 2019. Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 8% of the aggregate purchase price of the Units sold. The Company also agreed to reimburse the Placement Agent for its expenses in connection with this offering, up to $30,000, and agreed to reimburse the placement agent for its reasonable “blue sky” fees and expenses, of $5,000. The Placement Agency Agreement contains indemnification, representations, warranties, conditions precedent to closing and other provisions customary for transactions of this nature. Also pursuant to the Placement Agency Agreement, the Company, in connection with the offering, entered into Unit Purchase Option agreements, dated as of March 1, 2019 ( the “Unit Purchase Options”), pursuant to which the Company granted the Placement Agent or its assignees the right to purchase from the Company up to an aggregate of 69,250 Units (which represents 5% of the Units sold to investors in the offering) at an exercise price equal to 125% of the public offering price of the Units in the offering, or $1.125 per Unit. The Unit Purchase Options shall expire on February 27, 2024. On March 12, 2019, Peak One, one of the noteholders from the bridge loan, converted 71,046 shares of stock reducing the principal of the loan by $44,475. The value was computed, pursuant to the agreement, by calculating the average VWAP for the prior 20 days and multiplying that average by 70%. Dr. Carl Schwartz, the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional $1,300,000, see Note 10 – Related party Transactions. The Company entered into a forbearance agreement with L2 Capital, LLC and Peak One Opportunity Fund, LP. AS part of the agreement the Company added 15% to the principal of the note and issued inducement shares of common stock. The Company accrued approximately $503,000 in penalty expenses as a result as of December 31, 2018. This penalty expense is recorded in accrued expenses on the balance sheet. On March 26, 2019, Precision Therapeutics Inc., entered into a Placement Agency Agreement (the “Placement Agency Agreement”) pursuant to which Dawson James Securities, Inc. served as placement agent on a “best efforts” basis (the “Placement Agent”) for a registered direct offering in which the Company sold 1,478,750 shares of the Company’s common stock (“Common Stock”) and warrants to purchase up to 739,375 shares of Common Stock (the “Warrants”) (the “Offering”). The Common Stock and warrants were sold in units (the “Units”), with each Unit consisting of one share of Common Stock and a warrant to purchase 0.5 of a share of the Company’s Common Stock at an exercise price of $1.00 per whole share. The warrants are exercisable at any time on or after the date of issuance and expire on the fifth anniversary of issuance. The Units were sold at a price of $0.80 per Unit, resulting in gross proceeds to the Company of approximately $1.18 million, before deducting placement agent fees and estimated offering expenses. The net offering proceeds to the Company, after deducting the placement agent’s fees and other estimated offering expenses payable by the Company, are expected to be approximately $1.05 million. The closing of the Offering occurred on March 29, 2019. Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 8% of the aggregate purchase price of the Units sold. The Company also agreed to reimburse the Placement Agent for its expenses in connection with this offering, up to $30,000, and agreed to reimburse the placement agent for its reasonable “blue sky” fees and expenses, of $5,000. The Placement Agency Agreement contains indemnification, representations, warranties, conditions precedent to closing and other provisions customary for transactions of this nature. Also pursuant to the Placement Agency Agreement, the Company, in connection with the offering, entered into Unit Purchase Option agreements, dated as of March 29, 2019 ( the “Unit Purchase Options”), pursuant to which the Company granted the Placement Agent or its assignees the right to purchase from the Company up to an aggregate of 73,938 Units (which represents 5% of the Units sold to investors in the offering) at an exercise price equal to 125% of the public offering price of the Units in the offering, or $1.00 per Unit. The Unit Purchase Options shall expire on March 29, 2024. The securities in the Offerings were offered and sold pursuant to the Company’s “shelf” registration statement (File No. 333 - 213766 ), which was declared effective by the United States Securities and Exchange Commission on October 4, 2016.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Nature of Operations and Continuance of Operations

The Company was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to The NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, the Company’s common stock began trading under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

December 31, 2018,

the registrant had

14,091,748

shares of common stock, par value

$.01

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products.

The Company acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), in transactions in the

first

quarter of

2018,

and in

April 2018

the Company entered into a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In

June 2018,

the Company and Helomics entered into a definitive merger agreement – see Note

149,000

first

quarter, is presented as part of the consolidated financial statements (“financial statements”).

$63,107,945.

The Company does

not

expect to generate sufficient operating revenue to sustain its operations in the near-term. In

2018,

the Company incurred negative operating cash flows of approximately

$441,000

per month. Although the Company has attempted to curtail expenses, there is

guarantee that the Company will be able to reduce these expenses significantly, and expenses

may

need to be higher to prepare product lines for broader sales in order to generate sustainable revenues.

The Company had cash and cash equivalents of

$162,152

as of

December 31, 2018

one

year after the date that the financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty. The Company has available financing options including a shelf registration statement on Form S-

with which the Company has raised approximately

$2.1

million in net proceeds in early

2019.

The Company

may

raise up to approximately

$1.7

million in additional gross proceeds in the next calendar year using the shelf registration statement. This amount of available financing will increase to approximately

$6.4

million in additional gross proceeds, once the Helomics acquisition is completed.

Since inception to

December 31, 2018,

the Company raised approximately

$36,490,000

in equity and

$7,870,000

in debt financing. Equity raises include: a

January 2017

public offering of units with gross proceeds to the Company of

$3,937,500;

November 2017

private placement with gross proceeds of

$1,300,000;

and, a

January 2018

public offering with gross proceeds of

$2,755,000.

Included in debt financing were raises in

September 2018

on senior secured promissory notes with net proceeds of

$1,815,000,

and in

November 2018

the Company received a loan from the CEO for

$370,000.

Subsequent to

December 31, 2018,

the Company’s CEO made an additional loan to the Company and made a private investment in the Company’s common stock, which in total, generated an additional

$1,300,000.

The Company has

commitments or contingencies.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Developments

Accounting Policies and Estimates

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning

January

2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018,

and there was

material impact. See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

not

result in consolidation and are

not

January 1, 2018.

As of

December 31, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. The Company adopted ASU

2016

January 1, 2019,

using the transition relief to the modified retrospective approach, presenting prior year information based on the previous standard. The adoption resulted in

material impact to the Company’s balance sheet, results of operations, equity or cash flows.

August 2016,

the FASB issued ASU

No.

2016

15,

Statement of Cash Flows (Topic

230

): Classification of Certain Cash Receipts and Cash Payments,

December 15, 2017,

January 1, 2018.

As of

December 31, 2018,

there is

material impact on the Company’s financial statements and disclosures.

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment in accordance with ASC

360

— Intangibles —Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount

may

not

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

Advertising Costs, Policy [Policy Text Block]

Advertising

Advertising costs are expensed as incurred. Advertising expenses were

$43,548

2018

and

$37,060

2017.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs were approximately

$526,000

and

$289,000

for

2018

and

2017,

respectively.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

may,

at its discretion, negotiate different shipping terms with customers which

may

affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally

Customers

may

also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of

one

year subsequent to the

one

Variable Consideration

not

contain any features that create variability in the amount or timing of revenue to be earned.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value.

Certificates of Deposit Policy [Policy Text Block]

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s

Accounting Standards Certification

(ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities, which in

2018

are cash equivalents only, were determined based on Level

inputs.

Receivables, Policy [Policy Text Block]

Receivables

not

been material to the financial statements.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	December 31, 2018		December 31, 2017

Finished goods	$	58,701	$	62,932
Raw materials		127,003		141,028
Work-In-Process		55,362		61,085
Total	$	241,066	$	265,045

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

The Company’s investment in fixed assets consists of the following:

	December 31, 2018		December 31, 2017
Computers and office equipment	$	204,903	$	183,528
Leasehold Improvements		140,114		25,635
Manufacturing Tooling		108,955		108,955
Demo Equipment		85,246		43,368
Total		539,218		361,486
Less: Accumulated Depreciation		358,765		273,770
Total Fixed Assets, Net	$	180,453	$	87,716

Depreciation expense was

$84,995

2018

and

$58,872

2017.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

The components of intangible assets all of which are finite-lived were as follows:

	12/31/2018							12/31/2017
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	318,304	$	(182,559	)	$	135,745	$	264,032	$	(168,676	)	$	95,356
Licensing Fees		877,500		(48,750	)		828,750		-		-			-
Total	$	1,195,804	$	(231,309	)	$	964,495	$	264,032	$	(168,676	)	$	95,356

The following table outlines the estimated future amortization expense related to intangible assets held as of

December 31, 2018

Year ending	Expense
2019		72,383
2020		72,383
2021		72,383
2022		72,383
2023		72,383
Thereafter		602,580
Total		964,495

Intangible assets consist of trademarks, patent costs and licensing fees. Amortization expense was

$62,633

2018

and

$12,689

2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Tax, Policy [Policy Text Block]

Income Taxes

December 22, 2017,

the Tax Cuts and Jobs Act of

2017

34%

21%.

As a result of the enacted law, the Company was required to value its deferred tax assets and liabilities at the new enacted rate. There was

income tax impact from the re-measurement due to the

100%

valuation allowance on the Company’s deferred tax assets.

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Offering Costs [Policy Text Block]

Offering Costs

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Credit Risk

one

financial institution. The Company has

credit risk concentration because there are

funds in excess of insurance limits in a single bank.

Standard Product Warranty, Policy [Policy Text Block]

Product Warranty Costs

2018

and in

2017,

the Company incurred approximately

$10,682

and

$6,209,

respectively in warranty costs.

Segment Reporting, Policy [Policy Text Block]

Segments

The Company operates in

two

December 31, 2018

and

2017

were located at or derived from operations in the United States. In

2018

and

2017,

business activity within the Company’s international segment was immaterial.

Risks and Uncertainties Policy [Policy Text Block]

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

Note 1 - Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	December 31, 2018		December 31, 2017

Finished goods	$	58,701	$	62,932
Raw materials		127,003		141,028
Work-In-Process		55,362		61,085
Total	$	241,066	$	265,045

Property Plant and Equipment Useful Life [Table Text Block]

Property, Plant and Equipment [Table Text Block]

	December 31, 2018		December 31, 2017
Computers and office equipment	$	204,903	$	183,528
Leasehold Improvements		140,114		25,635
Manufacturing Tooling		108,955		108,955
Demo Equipment		85,246		43,368
Total		539,218		361,486
Less: Accumulated Depreciation		358,765		273,770
Total Fixed Assets, Net	$	180,453	$	87,716

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	12/31/2018							12/31/2017
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	318,304	$	(182,559	)	$	135,745	$	264,032	$	(168,676	)	$	95,356
Licensing Fees		877,500		(48,750	)		828,750		-		-			-
Total	$	1,195,804	$	(231,309	)	$	964,495	$	264,032	$	(168,676	)	$	95,356

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Year ending	Expense
2019		72,383
2020		72,383
2021		72,383
2022		72,383
2023		72,383
Thereafter		602,580
Total		964,495

Note 2 - Equity Method Investment (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Equity Method Investments [Table Text Block]

	December 31, 2018

Current assets	$	419,266

Non-current assets	$	2,046,347

Total assets	$	2,465,613

Current liabilities	$	12,247,174

Total liabilities	$	12,247,174

	For the Year-ended Ended
	December 31, 2018
Revenue	$	523,546

Gross margin	$	214,426

Net loss on operations	$	(5,056,725	)

Net loss	$	(9,452,835	)

Net Loss to investee	$	(7,159,255	) 1

Note 4 - Stockholders’ Equity (Deficit), Stock Options and Warrants (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Share-based Compensation, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		1,098,858			1.01		2,336,154			1.07
Expired		(194,564	)		2.00		(10,706	)		199.55
Exercised		-			-		(650,062	)		1.00

Outstanding at December 31, 2018		3,669,277		$	1.70		3,626,643		$	4.17

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Exercise Prices	Shares		Weighted Average Remaining Life
Options:
$0.619		201,908		10.00
$0.82		60,000		9.91
$0.91		10,000		9.30
$0.965		3,000		9.38
$0.97		191,753		9.02
$1.01		149,110		9.12
$1.06		23,585		9.76
$1.10		86,958		9.46
$1.13		195,931		9.55
$1.15		21,740		9.59
$1.16		66,451		9.59
$1.18		30,000		9.61
$1.20		41,668		9.59
$1.21		30,000		9.61
$1.35		111,112		9.20
$1.454		17,200		8.75
$1.47		2,305,790		8.48
$2.10		14,286		8.25
$2.25		293		7.65
$2.42		20,640		7.64
$2.80		57,145		8.01
$3.75		4,000		7.50
$4.125		3,636		7.75
$4.1975		7,147		7.72
$4.25		3,529		7.25
$5.125		3,902		7.69
$65.75		190		6.81
$73.50		1,157		7.01
$77.50		2,323		6.50
$80.25		187		6.75
$86.25		232		6.25
$131.25		81		3.69
$148.125		928		4.21
$150.00		1,760		3.63
$162.50		123		6.01
$206.25		121		5.75
$248.4375		121		4.54
$262.50		130		4.54
$281.25		529		4.04
$318.75		3		4.35
$346.875		72		5.25
$431.25		306		5.19
$506.25		188		5.00
$596.25		42		4.75
Total		3,669,277

Warrants:
$0.836		221,292		4.92
$1.00		1,063,935		3.76
$1.07		697,946		3.85
$1.155		1,071,776		4.75
$1.3125		86,086		4.75
$2.25		385,000		3.06
$123.75		94,084		1.67
$243.75		2,529		0.59
$309.375		2,850		0.61
$309.50		222		0.85
$506.25		59		0.12
$609.375		862		0.09
Total		3,626,643

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

Year	Shares		Price
2011		173			281.25
2012		1,841		131.25	–	150.00
2013		1,553		148.13	–	596.25
2014		836		162.50	–	431.25
2015		4,088		65.75	–	86.25
2016		100,294		2.25	–	5.13
2017		2,461,634		1.01	–	2.10
2018		1,098,858		0.62	–	1.35
Total		3,669,277		$0.62	–	596.25

Year	Shares		Price
2014		6,455		243.75	–	609.38
2015		94,151		0.00	–	243.75
2016		252,333			1.00
2017		1,082,946		1.07	–	2.25
2018		2,190,758		0.84	–	1.3125
Total		3,626,643		$0.00	–	609.38

Note 7 - Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year Ended December 31,
	2018			2017
Numerator:
Net loss available in basic and diluted	$	(10,086,477	)	$	(6,003,017	)

Denominator:
Weighted average common shares outstanding-basic		12,816,289			6,362,989

Effect of dilutive stock options warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-diluted		12,816,289			6,362,989

Loss per common share-basic and diluted	$	(0.79	)	$	(0.94	)

Note 8 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2018			2017
Statutory federal income tax benefit	$	2,118,160		$	2,633,841
State tax benefit, net of federal taxes		66,117			76,922
Foreign tax benefit		132,931			-
Foreign operations tax rate differential		(94,373	)		-
State rate adjustment		15,355			(77,556	)
R&D tax credit		22,532			-
Nondeductible/nontaxable items		(118,905	)		(757,149	)
State NOL adjustment		746,479			-
OID and derivatives		(159,037	)		-
NQSO adjustment		-			537,884
New federal rate adjustment		-			(4,974,121	)
Other		47,868			(8,336	)
Valuation allowance decrease (increase)		(2,777,127	)		2,568,515
Total income tax benefit (expense)	$	-		$	-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	2018			2017
Deferred tax assets:
Noncurrent:
Depreciation	$	4,488		$	3,251
Inventory		6,991			6,950
Compensation accruals		60,905			50,436
Accruals and reserves		77,777			64,732
Charitable contribution carryover		3,972			4,068
Derivatives		57,276			-
Related party investments		481,652			-
Intangibles		2,020			-
NQSO compensation		1,019,139			766,648
NOL and credits		9,655,388			7,479,505
Total deferred tax assets		11,369,608			8,375,590

Deferred tax liabilities:
Noncurrent:
Original issue discount		(216,891	)		-
Total deferred tax liabilities		(216,891	)		-

Net deferred tax assets		11,152,717			8,375,590
Less: valuation allowance		(11,152,717	)		(8,375,590	)
Total	$	-		$	-

Note 9 - Rent Obligation (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Rent Expense [Table Text Block]

2019	$	80,320
2020		82,320
2021		43,320
2022		40,320
2023		40,320
Thereafter		161,280

Note 1 - Summary of Significant Accounting Policies (Details Textual)				1 Months Ended							3 Months Ended	12 Months Ended		202 Months Ended
	Mar. 12, 2019 USD ($)	Feb. 06, 2019 USD ($)	Jan. 08, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) $ / shares shares	Nov. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jan. 31, 2018 USD ($)	Nov. 30, 2017 USD ($)	Jan. 31, 2017 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Mar. 22, 2019 $ / shares	Jul. 11, 2018 $ / shares	Jul. 10, 2018 $ / shares	Mar. 31, 2018	Feb. 21, 2018 $ / shares	Dec. 28, 2017 $ / shares	Apr. 19, 2017 $ / shares
Common Stock, Shares, Outstanding, Ending Balance \| shares					14,091,748							14,091,748	6,943,283	14,091,748
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.01							$ 0.01	$ 0.01	$ 0.01		$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance					$ (63,107,945)							$ (63,107,945)	$ (53,021,469)	$ (63,107,945)
Net Cash Provided by (Used in) Operating Activities, Per Month												441,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance					162,152							162,152	766,189	162,152
Stockholders' Equity, Period Increase (Decrease), Total														36,490,000
Debt Instrument, Increase (Decrease), Net, Total														7,870,000
Advertising Expense												43,548	37,060
Research and Development Expense, Total												$ 526,000	289,000
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice												1 year
Depreciation, Total												$ 84,995	58,872
Amortization of Intangible Assets, Total												62,633	12,689
Unrecognized Tax Benefits, Ending Balance					0							0		0
Cash, Uninsured Amount					0							0		$ 0
Product Warranty Expense												$ 10,682	$ 6,209
Number of Operating Segments												2
Maintenance [Member]
Revenue, Performance Obligation, Timing												1 year
Minimum [Member]
Standard Payment Term for Customers												30 days
Maximum [Member]
Standard Payment Term for Customers												60 days
Chief Executive Officer [Member]
Proceeds from Related Party Debt					$ 370,000	$ 370,000
Convertible Promissory Note [Member]
Proceeds from Debt, Net of Issuance Costs							$ 1,815,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares															$ 0.01
Subsequent Event [Member] \| Chief Executive Officer [Member]
Proceeds from Related Party Debt	$ 1,300,000	$ 300,000	$ 950,000								$ 1,300,000
Shelf Registration [Member] \| Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 1,100,000							2,100,000
Additional Gross Proceeds From Sale of Equity, Available to Raise				$ 1,700,000							1,700,000
Stock Issuance Plan, Additional Available Amount											$ 6,400,000
IPO [Member]
Proceeds from Issuance or Sale of Equity, Total										$ 3,937,500
Private Placement [Member] \| Series C Convertible Preferred Stock [Member]
Proceeds from Issuance or Sale of Equity, Total									$ 1,300,000
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total								$ 2,755,000
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage																		25.00%

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Finished goods	$ 58,701	$ 62,932
Raw materials	127,003	141,028
Work-In-Process	55,362	61,085
Total	$ 241,066	$ 265,045

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	12 Months Ended
	Dec. 31, 2018
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant, and Equipment Gross	$ 539,218	$ 361,486
Less: Accumulated Depreciation	358,765	273,770
Total Fixed Assets, Net	180,453	87,716
Office Equipment [Member]
Property, Plant, and Equipment Gross	204,903	183,528
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	140,114	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 85,246	$ 43,368

Note 1 - Summary of Significant Accounting Policies - Components of Intangible Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Gross Carrying Costs	$ 1,195,804	$ 264,032
Accumulated Amortization	(231,309)	(168,676)
Net Carrying Amount	964,495	95,356
Patents and Trademarks [Member]
Gross Carrying Costs	318,304	264,032
Accumulated Amortization	(182,559)	(168,676)
Net Carrying Amount	135,745	95,356
Licensing Agreements [Member]
Gross Carrying Costs	877,500
Accumulated Amortization	(48,750)
Net Carrying Amount	$ 828,750

Note 1 - Summary of Significant Accounting Policies - Estimated Future Amortization Expense (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
2019	$ 72,383
2020	72,383
2021	72,383
2022	72,383
2023	72,383
Thereafter	602,580
Total	$ 964,495	$ 95,356

Note 2 - Equity Method Investment (Details Textual) - Helomics Holding Corp. [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 27, 2018
Equity Method Investment, Ownership Percentage	75.00%	80.00%
Equity Method Investment, Summarized Financial Information, Revenue	$ 523,546
Financing Receivable, Net, Total	413,683
Financing Receivable, Gross	1,165,013
Fair Value Adjustment of Notes Receivable	(751,330)
Equity Method Investments	0
Contract Research Organization and D-CHIP Artificial Intelligence Products [Member]
Equity Method Investment, Summarized Financial Information, Revenue	$ 31,000

Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details)

12 Months Ended

Dec. 31, 2018

USD ($)

Gross margin

$ (5,056,725)

Net loss

(9,452,835)

Helomics Holding Corp. [Member]

419,266

2,046,347

2,465,613

12,247,174

12,247,174

523,546

214,426

$ (7,159,255)

^[1]

[1]	The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 - February 27, 2018, and then at 75% for the remainder of the twelve-month period at the current equity investment percentage owned by the Company.

Note 3 - Revenue Recognition (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Jan. 07, 2019	Dec. 31, 2017
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, Net, Current, Total	$ 232,602	$ 232,602	$ 137,499
Contract with Customer, Liability, Current	$ 23,065		$ 6,663
Maintenance [Member]
Revenue, Performance Obligation, Timing	1 year
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders’ Equity (Deficit), Stock Options and Warrants (Details Textual)											1 Months Ended		3 Months Ended		12 Months Ended
	Oct. 26, 2018 USD ($) $ / shares shares	Jul. 11, 2018 $ / shares shares	Jul. 10, 2018 $ / shares shares	Mar. 12, 2018 $ / shares shares	Feb. 21, 2018 USD ($) $ / shares shares	Jan. 15, 2018 $ / shares shares	Jan. 11, 2018 USD ($) shares	Nov. 30, 2017 USD ($) $ / shares shares	Apr. 19, 2017 $ / shares shares	Jan. 19, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Jan. 31, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Mar. 22, 2019 $ / shares shares	Jan. 02, 2018 shares	Dec. 28, 2017 $ / shares shares	Jan. 29, 2017 shares	Oct. 27, 2016 shares
Shares Issued, Price Per Share \| $ / shares		$ 1.17	$ 1.18
Proceeds from Issuance of Convertible Preferred Stock \| $																$ 1,300,001
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.01	$ 0.01		$ 0.01				$ 0.01		$ 0.01			$ 0.01	$ 0.01	$ 0.01			$ 0.01
Stock Issued During Period, Shares, Issued for Services			250,000
Stock Issued During Period, Share, Issued in Escrow		750,000
Common Stock, Shares Authorized											50,000,000			50,000,000	50,000,000	50,000,000			50,000,000	24,000,000	8,000,000
Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares									400,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate															0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number											2,946,488				2,946,488
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares											$ 1.79				$ 1.79
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term															8 years 313 days
Class of Warrant or Right Number of Warrants Vested and Exercisable											2,247,489				2,247,489
Allocated Share-based Compensation Expense, Total \| $															$ 1,124,928	$ 2,298,680
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $											$ 741,922				$ 741,922
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost \| $														$ 1,900,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares															$ 1.01	$ 1.45
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															1,098,858	2,612,070
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition															1 year 240 days
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares						$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares						$ 0.97
Number of Equal Installments Options are Expected to Vest						4
Vice President of Sales and Marketing [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares				$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				111,112
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares				$ 1.35
Number of Equal Installments Options are Expected to Vest				4
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares											$ 609.38				$ 609.38
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate															3.07%	2.40%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate															66.00%	66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term															10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares															$ 1.0044	$ 1.5489
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares											$ 0				$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate															2.33%	1.92%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate															59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term															5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares															$ 0.3816	$ 0.6541
Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															10 years
Equity Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period															3 years
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																		5,000,000
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares																	$ 0.01
Common Stock, Shares Authorized																	100,000,000
Helomics Holding Corp. [Member]
Notes Payable, Total \| $	$ 7,600,000
Helomics Holding Corp. [Member]
Convertible Preferred Stock Held, Conversion Feature, Percent	20.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow	860,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow, Period	1 year 180 days
Percentage of Holders of Acquiree's Promissory Note Agreeing to Merger	75.00%
Business Acquisition, Warrant Exchange Ratio	0.6
Helomics Holding Corp. [Member] \| Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000												1,100,000
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues							1,100,000
Share Exchange Agreement, Shares Received							2,500,000
Share Exchange Agreement, Convertible Notes Receivable \| $													$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock													5.00%
Share Exchange Agreement, Potential Interest													25.00%
Share Exchange Agreement, Number of Shares Held in Escrow													1,100,000
Share Exchange Agreement, Contingent Revenue, Minimum \| $							$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent							20.00%
Conversion from Series C Convertible Preferred Stock to Common Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion											1.167				1.167
Conversion of Stock, Shares Issued											1,250,269
Series C Convertible Preferred Stock [Member]
Stock Redeemed or Called During Period, Shares											142,466
Payments for Repurchase of Convertible Preferred Stock \| $											$ 189,285
Helomics Warrants Held by Investors [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	18,700,000
Helomics Warrants Held by Investors [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000,000
Precision Warrants [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1
Business Acquisition, Warrant Issued or Issuable, Exercise Price \| $ / shares	$ 1
Business Acquisition, Equity Interest Issued or Issuable from Exchange of Warrants	23,700,000
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights	14,200,000
Helomics Warrants Held by Other Parties [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	597,000
Helomics Warrants Held by Other Parties [Member] \| Helomics Holding Corp. [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	995,000
The 2017 Public Offering [Member]
Stock Issued During Period, Shares, New Issues										1,750,000
Shares Issued, Price Per Share \| $ / shares										$ 2.25
Share Per Each Unit										1
Proceeds from Issuance or Sale of Equity, Total \| $										$ 3,937,500
The 2017 Public Offering [Member] \| Series D Warrants [Member]
Class of Warrant or Right, Issued per Unit										0.2
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right										1
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 2.25
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues					215,247					175,000
Shares Issued, Price Per Share \| $ / shares					$ 0.9497
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 0.01
Proceeds from Issuance or Sale of Equity, Total \| $										$ 358,312
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										35,000
Sale of Stock, Underwriter Option Term												45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase												290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase												87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase \| $ / shares												$ 0.001
Proceeds from Underwriter Shares Exercised, Net \| $					$ 188,066
Stock Issued During Period, Underwriter Discount \| $					$ 16,354
Underwriter Discount Percentage					8.00%
Private Placement [Member]
Proceeds from Issuance of Convertible Preferred Stock \| $								$ 1,300,000
Private Placement [Member] \| Series C Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues								1,213,819
Shares Issued, Price Per Share \| $ / shares								$ 1.071
Private Placement [Member] \| The 2017 Private Placement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares								$ 1.26
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								606,910
Warrants and Rights Outstanding, Term								5 years 182 days
Class of Warrant or Right, Vesting Period								180 days
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues												2,900,000
Share Per Each Unit												1
Proceeds from Issuance or Sale of Equity, Total \| $												$ 2,755,000
Share Price \| $ / shares												$ 0.95
The 2018 Public Offering [Member] \| Series E Warrants [Member]
Class of Warrant or Right, Issued per Unit												0.3
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right												1
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares												$ 1

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares Outstanding (in shares)	3,669,277
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 52.22
Number of Shares Issued (in shares)	2,336,154	1,082,946
Average Exercise Price Issued (in dollars per share)	$ 1.07	$ 1.49
Number of Shares Expired (in shares)	(10,706)	(2,790)
Average Exercise Price Expired (in dollars per share)	$ 199.55	$ 281.46
Number of Shares Exercised (in shares)	(650,062)
Average Exercise Price Exercised (in dollars per share)	$ 1
Number of Shares Outstanding (in shares)	3,626,643	1,951,257
Average Exercise Price Outstanding (in dollars per share)	$ 4.17	$ 23.74
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 11.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,098,858	2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.01	$ 1.45
Number of Shares Expired (in shares)	(194,564)	(12,730)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 10.39
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	3,669,277	2,764,983
Average Exercise Price Outstanding (in dollars per share)	$ 1.70	$ 2

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2018 shares
Shares, options (in shares)	3,669,277
Shares, warrants (in shares)	3,626,643
Warrant One [Member]
Shares, warrants (in shares)	221,292
Weighted average remaining life, warrants (Year)	4 years 335 days
Warrant Two [Member]
Shares, warrants (in shares)	1,063,935
Weighted average remaining life, warrants (Year)	3 years 277 days
Warrant Three [Member]
Shares, warrants (in shares)	697,946
Weighted average remaining life, warrants (Year)	3 years 310 days
Warrant Four [Member]
Shares, warrants (in shares)	1,071,776
Weighted average remaining life, warrants (Year)	4 years 273 days
Warrant Five [Member]
Shares, warrants (in shares)	86,086
Weighted average remaining life, warrants (Year)	4 years 273 days
Warrant Six [Member]
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	3 years 21 days
Warrant Seven [Member]
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	1 year 244 days
Warrant Eight [Member]
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	215 days
Warrant Nine [Member]
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	222 days
Warrant Ten [Member]
Shares, warrants (in shares)	222
Weighted average remaining life, warrants (Year)	310 days
Warrant Eleven [Member]
Shares, warrants (in shares)	59
Weighted average remaining life, warrants (Year)	43 days
Warrant Twelve [Member]
Shares, warrants (in shares)	862
Weighted average remaining life, warrants (Year)	32 days
Warrant Thirteen [Member]
Shares, warrants (in shares)	3,626,643
Weighted average remaining life, warrants (Year)
Stock Options One [Member]
Shares, options (in shares)	201,908
Weighted average remaining life, options (Year)	10 years
Stock Options Two [Member]
Shares, options (in shares)	60,000
Weighted average remaining life, options (Year)	9 years 332 days
Stock Options Three [Member]
Shares, options (in shares)	10,000
Weighted average remaining life, options (Year)	9 years 109 days
Stock Options Four [Member]
Shares, options (in shares)	3,000
Weighted average remaining life, options (Year)	9 years 138 days
Stock Options Five [Member]
Shares, options (in shares)	191,753
Weighted average remaining life, options (Year)	9 years 7 days
Stock Options Six [Member]
Shares, options (in shares)	149,110
Weighted average remaining life, options (Year)	9 years 43 days
Stock Options Seven [Member]
Shares, options (in shares)	23,585
Weighted average remaining life, options (Year)	9 years 277 days
Stock Options Eight [Member]
Shares, options (in shares)	86,958
Weighted average remaining life, options (Year)	9 years 167 days
Stock Options Nine [Member]
Shares, options (in shares)	195,931
Weighted average remaining life, options (Year)	9 years 200 days
Stock Options Ten [Member]
Shares, options (in shares)	21,740
Weighted average remaining life, options (Year)	9 years 215 days
Stock Options Eleven [Member]
Shares, options (in shares)	66,451
Weighted average remaining life, options (Year)	9 years 215 days
Stock Options Twelve [Member]
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 222 days
Stock Options Thirteen [Member]
Shares, options (in shares)	41,668
Weighted average remaining life, options (Year)	9 years 215 days
Stock Options Fourteen [Member]
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 222 days
Stock Options Fifteen [Member]
Shares, options (in shares)	111,112
Weighted average remaining life, options (Year)	9 years 73 days
Stock Options Sixteen [Member]
Shares, options (in shares)	17,200
Weighted average remaining life, options (Year)	8 years 273 days
Stock Options Seventeen [Member]
Shares, options (in shares)	2,305,790
Weighted average remaining life, options (Year)	8 years 175 days
Stock Options Eighteen [Member]
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	8 years 91 days
Stock Options Nineteen [Member]
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	7 years 237 days
Stock Options Twenty [Member]
Shares, options (in shares)	20,640
Weighted average remaining life, options (Year)	7 years 233 days
Stock Options Twenty One [Member]
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Twenty Two [Member]
Shares, options (in shares)	4,000
Weighted average remaining life, options (Year)	7 years 182 days
Stock Options Twenty Three [Member]
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	7 years 273 days
Stock Options Twenty Four [Member]
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	7 years 262 days
Stock Options Twenty Five [Member]
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	7 years 91 days
Stock Options Twenty Six [Member]
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	7 years 251 days
Stock Options Twenty Seven [Member]
Shares, options (in shares)	190
Weighted average remaining life, options (Year)	6 years 295 days
Stock Options Twenty Eight [Member]
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Twenty Nine [Member]
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	6 years 182 days
Stock Options Thirty [Member]
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	6 years 273 days
Stock Options Thirty-One [Member]
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	6 years 91 days
Stock Options Thirty-Two [Member]
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	3 years 251 days
Stock Options Thirty-Three [Member]
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	4 years 76 days
Stock Options Thirty-Four [Member]
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	3 years 229 days
Stock Options Thirty-Five [Member]
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	6 years 3 days
Stock Options Thirty-Six [Member]
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	5 years 273 days
Stock Options Thirty-Seven [Member]
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	4 years 197 days
Stock Options Thirty-Eight [Member]
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	4 years 197 days
Stock Options Thirty-Nine [Member]
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	4 years 14 days
Stock Options Forty [Member]
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	4 years 127 days
Stock Options Forty-One [Member]
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	5 years 91 days
Stock Options Forty-Two [Member]
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	5 years 69 days
Stock Options Forty-Three [Member]
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	5 years
Stock Options Forty-Four [Member]
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	4 years 273 days
Stock Options Forty-Five [Member]
Shares, options (in shares)	3,669,277
Weighted average remaining life, options (Year)

Note 4 - Stockholders' Equity (Deficit) , Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	Dec. 31, 2018 $ / shares shares
Shares, options (in shares) \| shares	3,669,277
Shares, warrants (in shares) \| shares	3,626,643
Minimum [Member]
Price, options (in dollars per share)	$ 0.62
Warrant exercises, exercise price per share (in dollars per share)	0
Maximum [Member]
Price, options (in dollars per share)	596.25
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38
Warrants 2014 [Member]
Shares, warrants (in shares) \| shares	6,455
Warrants 2014 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75
Warrants 2014 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares) \| shares	94,151
Warrants 2015 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0
Warrants 2015 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares) \| shares	252,333
Warrant exercises, exercise price per share (in dollars per share)	$ 1
Warrants 2017 [Member]
Shares, warrants (in shares) \| shares	1,082,946
Warrants 2017 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.07
Warrants 2017 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares) \| shares	2,190,758
Warrants 2018 [Member] \| Minimum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 0.84
Warrants 2018 [Member] \| Maximum [Member]
Warrant exercises, exercise price per share (in dollars per share)	$ 1.3125
Stock Options 2011 [Member]
Shares, options (in shares) \| shares	173
Price, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares) \| shares	1,841
Stock Options 2012 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares) \| shares	1,553
Stock Options 2013 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 148.13
Stock Options 2013 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares) \| shares	836
Stock Options 2014 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares) \| shares	4,088
Stock Options 2015 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares) \| shares	100,294
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares) \| shares	2,461,634
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.01
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares) \| shares	1,098,858
Stock Options 2018 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0.62
Stock Options 2018 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 1.35

Note 5 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended							2 Months Ended	3 Months Ended	5 Months Ended	12 Months Ended
Note 5 - Notes Receivable (Details Textual) - USD ($)	Mar. 31, 2019	Dec. 31, 2018	Oct. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Oct. 31, 2017	Feb. 28, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2018	Jul. 31, 2017
Subsequent Event [Member] \| Shelf Registration [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 1,100,000								$ 2,100,000
Advance to Helomics [Member]
Payments to Acquire Notes Receivable							$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable				$ 60,000		$ 67,512
Lease to Purchase Equipment, Down Payment, Percentage						50.00%
CytoBioscience [Member] \| Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage					8.00%							8.00%
Financing Receivable, Net, Total					$ 1,112,524	$ 1,070,000
Notes Receivable, Term					2 years
Proceeds from Collection of Notes Receivable										$ 0
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total				$ 163,468
Payments to Acquire Notes Receivable		$ 30,000	$ 907,500
Share Exchange Agreement, Outstanding Receivables, Amount Converted					$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables					833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock					5.00%
Investment, Ownership Percent					25.00%
Financing Receivable, Gross		1,165,013								1,165,013	$ 1,165,013
Interest Receivable		$ 29,215								$ 29,215	29,215
Fair Value Adjustment of Notes Receivable											$ (751,330)
Helomics Holding Corp. [Member] \| Subsequent Event [Member]
Payments to Acquire Notes Receivable								$ 305,000
Financing Receivable, Gross	1,890,013								$ 1,890,013
Helomics Holding Corp. [Member] \| Subsequent Event [Member] \| Shelf Registration [Member]
Payments to Acquire Notes Receivable	$ 420,000

Note 6 - Convertible Debt and Derivative Liability (Details Textual)	Mar. 31, 2019 USD ($) shares	Oct. 26, 2018	Oct. 03, 2018 $ / shares shares	Dec. 31, 2018 USD ($) yr $ / shares	Sep. 30, 2018 USD ($)	Sep. 28, 2018 USD ($)
Stock Issued During Period, Shares, Inducement for Bridge Loan \| shares			650,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 609.38
Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares			1,071,776
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 1.155
Class of Warrant or Right, Vesting Period		180 days
Warrants and Rights Outstanding, Term			5 years
Class of Warrant or Right, Fair Value per Warrant \| $ / shares				$ 0.5361
Warrants and Rights Outstanding						$ 574,631
Derivative Liability, Total				$ 272,745	$ 645,008
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0.0294
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input \| yr				5
Warrants in Connection with Convertible Promissory Note [Member] \| Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				0.59
Subsequent Event [Member] \| Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	1,336,805
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member]
Debt Instrument, Face Amount						$ 2,297,727
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Interest Guaranteed Period			1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock			70.00%
Debt Instrument, Convertible, Threshold Trading Days			20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares \| shares			2,678,328
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Maximum [Member]
Debt Instrument, Convertible, Conversion Price \| $ / shares			$ 1
Securities Purchase Agreements [Member] \| Convertible Promissory Note [Member] \| Subsequent Event [Member]
Debt Instrument, Face Amount	$ 2,865,909
Proceeds from Notes Payable, Total	$ 500,000

Note 7 - Loss Per Share (Details Textual) - shares	12 Months Ended
Note 7 - Loss Per Share (Details Textual) - shares	Dec. 31, 2018	Dec. 31, 2017
Weighted Average Number of Shares, Contingently Issuable	3,294,087
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,295,921	4,716,240
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Net loss

$ (10,086,477)

$ (6,003,017)

Weighted average common shares outstanding-basic (in shares)

12,816,289

6,362,989

Effect of dilutive stock options warrants and preferred stock (1) (in shares)

^[1]

Weighted average common shares outstanding-diluted (in shares)

12,816,289

6,362,989

Loss per common share - basic and diluted (in dollars per share)

$ (0.79)

$ (0.94)

[1]

The number of shares underlying options and warrants outstanding as of December 31, 2018 and December 31, 2017 are 7,295,921 and 4,716,240, respectively. The number of shares underlying the preferred stock as of December 31, 2018 is 79,246 for Series B Convertible. The number of shares underlying the convertible debt is 3,294,087. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
Note 8 - Income Taxes (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		$ 0
Valuation Allowance Percentage	100.00%	100.00%
Federal Income Tax Expense (Benefit), Continuing Operations, Total	$ 0
Open Tax Year	2014 2015 2016 2017 2018
Unrecognized Tax Benefits, Ending Balance	$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	$ 0
State and Local Income Tax Expense (Benefit), Continuing Operations, Total	0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	40,094,472	34,529,255
Operating Loss Carryforwards, Valuation Allowance, Total	9,603,237	8,129,778
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	12,940,458	12,261,799
Operating Loss Carryforwards, Valuation Allowance, Total	1,416,758	$ 245,812
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total	421,782
Operating Loss Carryforwards, Valuation Allowance, Total	$ 132,722

Note 8 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statutory federal income tax benefit	$ 2,118,160	$ 2,633,841
State tax benefit, net of federal taxes	66,117	76,922
Foreign tax benefit	132,931
Foreign operations tax rate differential	(94,373)
State rate adjustment	15,355	(77,556)
R&D tax credit	22,532
Nondeductible/nontaxable items	(118,905)	(757,149)
State NOL adjustment	746,479
OID and derivatives	(159,037)
NQSO adjustment		537,884
New federal rate adjustment		(4,974,121)
Other	47,868	(8,336)
Valuation allowance decrease (increase)	(2,777,127)	2,568,515
Total income tax benefit (expense)

Note 8 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Depreciation	$ 4,488	$ 3,251
Inventory	6,991	6,950
Compensation accruals	60,905	50,436
Accruals and reserves	77,777	64,732
Charitable contribution carryover	3,972	4,068
Derivatives	57,276
Related party investments	481,652
Intangibles	2,020
NQSO compensation	1,019,139	766,648
NOL and credits	9,655,388	7,479,505
Total deferred tax assets	11,369,608	8,375,590
Deferred tax liabilities:
Original issue discount	(216,891)
Total deferred tax liabilities	(216,891)
Net deferred tax assets	11,152,717	8,375,590
Less: valuation allowance	(11,152,717)	(8,375,590)
Total

Note 9 - Rent Obligation (Details Textual)		12 Months Ended
Note 9 - Rent Obligation (Details Textual)	Jun. 15, 2018 EUR (€) ft²	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Feb. 01, 2018 ft²
Operating Leases, Rent Expense, Total \| $		$ 69,013	$ 66,122
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract				3 years
Area of Real Estate Property				5,773
Corporate Office, Minnesota [Member] \| Office Space [Member]
Area of Real Estate Property				2,945
Corporate Office, Minnesota [Member] \| Manufacturing Facility [Member]
Area of Real Estate Property				2,828
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property	2,000
Lessee, Operating Lease, Monthly Rent \| €	€ 3,000
Skyline Medical Europe’s Offices Lease [Member] \| Office Space [Member]
Area of Real Estate Property	1,250
Skyline Medical Europe’s Offices Lease [Member] \| Storage Space [Member]
Area of Real Estate Property	300

Note 9 - Rent Obligation - Rent Obligation (Details)	Dec. 31, 2018 USD ($)
2019	$ 80,320
2020	82,320
2021	43,320
2022	40,320
2023	40,320
Thereafter	$ 161,280

Note 10 - Related Party Transactions (Details Textual) - USD ($)					1 Months Ended		3 Months Ended	12 Months Ended
	Mar. 12, 2019	Feb. 06, 2019	Feb. 01, 2019	Jan. 08, 2019	Dec. 31, 2018	Nov. 30, 2018	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jul. 11, 2018	Jul. 10, 2018
Proceeds from Issuance of Common Stock								$ 2,959,509	$ 3,814,938
Shares Issued, Price Per Share										$ 1.17	$ 1.18
Schwartz Warrant First Tranche [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						221,292
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.836
Schwartz Warrant Second Tranche [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Share Limit				78,128
Schwartz Warrant Third Tranche [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		138,889
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.188
Class of Warrant or Right, Share Limit		1,108,596
Schwartz Warrant [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Additional Shares Increase, Percentage			0.50%
Class of Warrant or Right, Share Limit		2,818,350
Class of Warrant or Right, Share Limit Percentage		19.90%
Director [Member]
Related Party Transaction, Monthly Cash Payment								$ 12,000
Related Party Transaction, Contract Term								180 days
Chief Executive Officer [Member]
Proceeds from Related Party Debt					$ 370,000	$ 370,000
Chief Executive Officer [Member] \| Subsequent Event [Member]
Proceeds from Related Party Debt	$ 1,300,000	$ 300,000		$ 950,000			$ 1,300,000
Due to Related Parties, Total				$ 1,320,000
Stock Issued During Period, Shares, New Issues				78,125
Proceeds from Issuance of Common Stock				$ 50,000
Shares Issued, Price Per Share				$ 0.64
Cash Payment In Lieu of Share Increase As Percentage of Principal Balance of Note		0.50%
Chief Executive Officer [Member] \| Subsequent Event [Member] \| Schwartz Note [Member]
Debt Instrument, Face Amount		$ 1,620,000
Chief Executive Officer [Member] \| Schwartz Warrant Second Tranche [Member] \| Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				742,188
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.704
TumorGenesis [Member]
Ownership Percentage					100.00%			100.00%

Note 11 - Retirement Savings Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 51,647	$ 29,952
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 12 - Correction of Immaterial Misstatement to Prior Period Financial Statements (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
General and Administrative Expense, Total		$ 4,626,997	$ 4,050,307
Retained Earnings (Accumulated Deficit), Ending Balance	$ (53,021,469)	(63,107,945)	(53,021,469)
Operating Expenses, Total		$ 7,861,379	6,053,523
Overstatement of Investors Stock Compensation Expense and Additional Paid-in Capital [Member]
Quantifying Misstatement in Current Year Financial Statements, Amount			2,150,097
Overstatement of Investors Stock Compensation Expense and Additional Paid-in Capital [Member] \| Restatement Adjustment [Member]
General and Administrative Expense, Total	(2,150,097)
Retained Earnings (Accumulated Deficit), Ending Balance	(2,150,097)		(2,150,097)
Understatement of Employee Stock Compensation Expenses and Additional Paid-in Capital [Member]
Quantifying Misstatement in Current Year Financial Statements, Amount			406,522
Understatement of Employee Stock Compensation Expenses and Additional Paid-in Capital [Member] \| Restatement Adjustment [Member]
Retained Earnings (Accumulated Deficit), Ending Balance	$ 406,522		406,522
Operating Expenses, Total			406,522
Understatement of Deferred Tax Assets [Member]
Quantifying Misstatement in Current Year Financial Statements, Amount			$ 767,000

Note 13 - Subsequent Events (Details Textual) - USD ($)						1 Months Ended			3 Months Ended	12 Months Ended
Note 13 - Subsequent Events (Details Textual) - USD ($)	Mar. 26, 2019	Mar. 12, 2019	Mar. 01, 2019	Feb. 06, 2019	Jan. 08, 2019	Dec. 31, 2018	Nov. 30, 2018	Jan. 31, 2018	Mar. 31, 2019	Dec. 31, 2018	Jul. 11, 2018	Jul. 10, 2018
Shares Issued, Price Per Share											$ 1.17	$ 1.18
Debt Instrument, Penalty Expenses										$ 503,000
Chief Executive Officer [Member]
Proceeds from Related Party Debt						$ 370,000	$ 370,000
The 2018 Public Offering [Member]
Stock Issued During Period, Shares, New Issues								2,900,000
Share Per Each Unit								1
Proceeds from Issuance or Sale of Equity, Total								$ 2,755,000
Subsequent Event [Member] \| Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues					78,125
Shares Issued, Price Per Share					$ 0.64
Proceeds from Related Party Debt		$ 1,300,000		$ 300,000	$ 950,000				$ 1,300,000
Subsequent Event [Member] \| Peak One [Member] \| Bridge Loan [Member]
Debt Conversion, Converted Instrument, Shares Issued		71,046
Debt Conversion, Original Debt, Amount		$ 44,475
Subsequent Event [Member] \| Right to Purchase Units [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			69,250
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.125
Right to Purchase Units, Percentage			5.00%
Right to Purchase Units, Exercise Price Percentage			125.00%
Subsequent Event [Member] \| The 2019 Offering [Member]
Stock Issued During Period, Shares, New Issues			1,385,000
Share Per Each Unit			1
Shares Issued, Price Per Share			$ 0.90
Proceeds from Issuance or Sale of Equity, Total			$ 1,250,000
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs			$ 1,080,000
Underwriter Discount Percentage			8.00%
Placement Agent Offering Fees			$ 30,000
Placement Agent Blue Sky Fees			$ 5,000
Subsequent Event [Member] \| The 2019 Offering [Member] \| The 2019 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			692,500
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			0.5
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1
Subsequent Event [Member] \| The 2018 Public Offering [Member] \| The 2019 Offering Warrants [Member]
Warrants and Rights Outstanding, Term			5 years
Subsequent Event [Member] \| Placement Agency Agreement [Member]
Stock Issued During Period, Shares, New Issues	1,478,750
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	73,938
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1
Shares Issued, Price Per Share	$ 0.80
Proceeds from Issuance or Sale of Equity, Total	$ 1,180,000
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs	1,050,000
Placement Agent Offering Fees	30,000
Placement Agent Blue Sky Fees	$ 5,000
Right to Purchase Units, Percentage	5.00%
Right to Purchase Units, Exercise Price Percentage	125.00%
Unit Agreement Number of Shares of Common Stock Included in Each Unit	1
Unit Agreement Number of Warrants Included in Each Unit	0.5
Placement Fee, Percent of Gross Proceeds	8.00%
Subsequent Event [Member] \| Placement Agency Agreement [Member] \| Warrants Issued With Placement Agency Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	739,375
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1